These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

229 related items for PubMed ID: 9102059

  • 1. Nandrolone decanoate and intranasal calcitonin as therapy in established osteoporosis.
    Flicker L, Hopper JL, Larkins RG, Lichtenstein M, Buirski G, Wark JD.
    Osteoporos Int; 1997; 7(1):29-35. PubMed ID: 9102059
    [Abstract] [Full Text] [Related]

  • 2. Effects of nandrolone decanoate on bone mass in established osteoporosis.
    Passeri M, Pedrazzoni M, Pioli G, Butturini L, Ruys AH, Cortenraad MG.
    Maturitas; 1993 Nov; 17(3):211-9. PubMed ID: 8133796
    [Abstract] [Full Text] [Related]

  • 3. Effects of nandrolone decanoate therapy on bone mass and calcium metabolism in women with established post-menopausal osteoporosis: a double-blind placebo-controlled study.
    Gennari C, AgnusDei D, Gonnelli S, Nardi P.
    Maturitas; 1989 Sep; 11(3):187-97. PubMed ID: 2687645
    [Abstract] [Full Text] [Related]

  • 4. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
    Kaskani E, Lyritis GP, Kosmidis C, Galanos A, Andypas G, Chorianopoulos K, Giagiosis A, Iliadou K, Karagianis A, Katsimichas K, Koskinas A, Matsouka K.
    Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969
    [Abstract] [Full Text] [Related]

  • 5. The androgenic anabolic steroid nandrolone decanoate prevents osteopenia and inhibits bone turnover in ovariectomized cynomolgus monkeys.
    Jerome CP, Power RA, Obasanjo IO, Register TC, Guidry M, Carlson CS, Weaver DS.
    Bone; 1997 Apr; 20(4):355-64. PubMed ID: 9108356
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The effects of nandrolone decanoate on bone mass and metabolism in ovariectomized rats with osteopenia.
    Li X, Takahashi M, Kushida K, Shimizu S, Hoshino H, Suzuki M, Inoue T.
    J Bone Miner Metab; 2000 Apr; 18(5):258-63. PubMed ID: 10959614
    [Abstract] [Full Text] [Related]

  • 9. Effects of combined treatment with etidronate, nandrolone-decanoate and calcium on bone mineral density in postmenopausal women.
    Bolanca S, Korsić M, Dekanić D, Cvijetić S.
    Acta Med Croatica; 1998 Apr; 52(3):159-63. PubMed ID: 9818438
    [Abstract] [Full Text] [Related]

  • 10. A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial.
    Binkley N, Bolognese M, Sidorowicz-Bialynicka A, Vally T, Trout R, Miller C, Buben CE, Gilligan JP, Krause DS, Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) Investigators.
    J Bone Miner Res; 2012 Aug; 27(8):1821-9. PubMed ID: 22437792
    [Abstract] [Full Text] [Related]

  • 11. Nandrolone decanoate for men with osteoporosis.
    Hamdy RC, Moore SW, Whalen KE, Landy C.
    Am J Ther; 1998 Mar; 5(2):89-95. PubMed ID: 10099043
    [Abstract] [Full Text] [Related]

  • 12. Treatment of postmenopausal osteoporosis with continuous daily oral alendronate in comparison with either placebo or intranasal salmon calcitonin.
    Adami S, Baroni MC, Broggini M, Carratelli L, Caruso I, Gnessi L, Laurenzi M, Lombardi A, Norbiato G, Ortolani S.
    Osteoporos Int; 1993 Mar; 3 Suppl 3():S21-7. PubMed ID: 8298199
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Effects on the bones of nandrolone decanoate therapy in postmenopausal osteoporosis].
    Gennari C, Agnusdei D, Gonnelli S.
    Minerva Endocrinol; 1989 Mar; 14(1):69-74. PubMed ID: 2659955
    [Abstract] [Full Text] [Related]

  • 19. Double-blind placebo--controlled trial of nandrolone decanoate in postmenopausal osteoporosis.
    Chhaparwal M, Saraf ML.
    Indian J Med Sci; 1998 Jun; 52(6):236-8. PubMed ID: 9849033
    [No Abstract] [Full Text] [Related]

  • 20. Cross-over study of fat-corrected forearm mineral content during nandrolone decanoate therapy for osteoporosis.
    Need AG, Horowitz M, Walker CJ, Chatterton BE, Chapman IC, Nordin BE.
    Bone; 1989 Jun; 10(1):3-6. PubMed ID: 2736154
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.